Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 352

The DOI matches its Crossref record; 131 of the 131 references it cites were found in a registry or an index.

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer

Open access
Tilki, Derya, van den Bergh, Roderick C.N., Briers, Erik, Van den Broeck, Thomas, Brunckhorst, Oliver, Darraugh, Julie, Eberli, Daniel, De Meerleer, Gert, De Santis, Maria, Farolfi, Andrea, Gandaglia, Giorgio, Gillessen, Silke, Grivas, Nikolaos, Henry, Ann M., Lardas, Michael, J.L.H. van Leenders, Geert, Liew, Matthew, Linares Espinos, Estefania, Oldenburg, Jan, van Oort, Inge M., Oprea-Lager, Daniela E., Ploussard, Guillaume, Roberts, Matthew J., Rouvière, Olivier, Schoots, Ivo G., Schouten, Natasha, Smith, Emma J., Stranne, Johan, Wiegel, Thomas, Willemse, Peter-Paul M., Cornford, Philip·2024·European Urology

Abstract

BACKGROUND AND OBJECTIVE The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (PCa) have been updated. Here we provide a summary of the 2024 guidelines. METHODS The panel performed a literature review of new data, covering the time frame between 2020 and 2023. The guidelines were updated and a strength rating for each recommendation was added on the basis of a systematic review of the evidence. KEY FINDINGS AND LIMITATIONS Risk stratification for relapsing PCa after primary therapy may guide salvage therapy decisions. New treatment options, such as androgen receptor-targeted agents (ARTAs), ARTA + chemotherapy combinations, PARP inhibitors and their combinations, and prostate-specific membrane antigen-based therapy have become available for men with metastatic PCa. CONCLUSIONS AND CLINICAL IMPLICATIONS Evidence for relapsing, metastatic, and castration-resistant PCa is evolving rapidly. These guidelines reflect the multidisciplinary nature of PCa management. The full version is available online (http://uroweb.org/guideline/ prostate-cancer/). PATIENT SUMMARY This article summarises the 2024 guidelines for the treatment of relapsing, metastatic, and castration-resistant prostate cancer. These guidelines are based on evidence and guide doctors in discussing treatment decisions with their patients. The guidelines are updated every year.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2024.04.010

Cites

131 of 131 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 131 references

Cited by

See all 352

Metadata

Authors
Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., Gandaglia, G., Gillessen, S., Grivas, N., Henry, A. M., Lardas, M., J.L.H. van Leenders, G., Liew, M., Linares Espinos, E., Oldenburg, J., van Oort, I. M., Oprea-Lager, D. E., Ploussard, G., Roberts, M. J., Rouvière, O., Schoots, I. G., Schouten, N., Smith, E. J., Stranne, J., Wiegel, T., Willemse, P.-P. M., & Cornford, P.
Venue
European Urology
Publisher
Elsevier BV
Published
2024-08
Volume
86
Issue
2
Pages
164-182
ISSN
0302-2838 (ISSN-L)
OpenAlex
W4396231607
Cited by
352
References
131
FWCI
89.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2024.04.010
The paper
Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., Gandaglia, G., Gillessen, S., Grivas, N., Henry, A. M., Lardas, M., J.L.H. van Leenders, G., Liew, M., Linares Espinos, E., Oldenburg, J., . . . Cornford, P. (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2024.04.010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.